A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Ciuleanu, T. E.
Kurteva, G.
Ocvirk, J.
Beslija, S.
Koza, I.
Papamichael, D.
Vrbanec, D.
Brodowicz, T.
Scheithauer, W.
Zielinski, C. C.
机构：
[1] Inst Oncol Cluj, Cluj Napoca, Romania
[2] Sbalo Natl Oncol Ctr, Sofia, Bulgaria
[3] Inst Oncol, Ljubljana, Slovenia
[4] Inst Oncol, Sarajevo, Bosnia & Herceg
[5] Natl Canc Inst, Bratislava, Slovakia
[6] Banc Cyprus Oncol Ctr, Nicosia, Cyprus
[7] Univ Hosp Rebro, Zagreb, Croatia
[8] Med Univ Vienna, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4032
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, open-label cecog phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab and FOLFIRI plus cetuximab as first-line therapy in metastatic colorectal cancer (MCRC)
    Ciuleanu, T.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Beslija, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [2] A randomized, open-label phase 11 study evaluating the efficacy and safety of FOLFOX6+Cetuximab versus FOLFIRI plus Cetuximab as first-line therapy in patients with metastatic colorectal cancer
    Ciuleanu, T. E.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I.
    Papamichael, D.
    Wenczl, M.
    Brodowicz, T.
    Zielinski, C. C.
    Beslija, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 249 - 249
  • [3] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
    Beslija, S.
    Koza, I.
    Ocvirk, J.
    Ciuleanu, T.
    Kurteva, G.
    Papamichael, D.
    Vrbanec, D.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
  • [4] RELATIONSHIP BETWEEN KRAS STATUS AND EFFICACY OF FOLFOX6+CETUXIMAB OR FOLFIRI plus CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): THE CECOG/CORE1.2.001 TRIAL
    Ocvirk, J.
    Vrbanec, D.
    Beslija, S.
    Koza, I
    Ciuleanu, T.
    Papamichael, D.
    Wrba, F.
    Messinger, D.
    Zielinski, C.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2009, 20 : 17 - 17
  • [5] Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial
    Koza, I., Sr.
    Wrba, F.
    Vrbanec, D.
    Ocvirk, J.
    Ciuleanu, T. E.
    Beslija, S.
    Papamichael, D.
    Messinger, D.
    Zielinski, C. C.
    Brodowicz, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] RANDOMIZED PHASE II STUDY EVALUATING UFOX PLUS CETUXIMAB VERSUS FOLFOX4 PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER: FUTURE
    Douillard, Jean-Yves
    Zemelka, Tomasz
    Fountzilas, Georgios
    Barone, Carlo
    Schlichting, Michael
    Eggleton, S. Peter
    Srimuninnimit, Vichien
    ANNALS OF ONCOLOGY, 2012, 23 : 11 - 12
  • [7] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [9] Preliminary results of an open label, uncontrolled, multicenter, phase II study evaluating the efficacy and safety of xelox plus cetuximab as first-line therapy in patients with metastatic colorectal cancer
    Barroso, S. A.
    Sanches, E.
    Ferreira, J. M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sottomayor, C.
    Espirito Santo, J.
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
    Zhang, D.
    Bai, C.
    Zhang, J.
    Zhang, Y.
    Liu, T.
    Pan, H.
    Zhong, H.
    Lin, X.
    Qiu, W-S.
    Liu, Y.
    Yuan, X.
    Zhang, T.
    Yin, X.
    Deng, Y.
    Hu, X.
    Xu, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S582 - S582
12345